Skip to main content

Table 11 Selected phase I-II clinical trials conducted with AT-101 as a single (−single-) or combined therapeutic on untreated/pre-treated patients with Carboplatin (CARB), Paclitaxel (PAC), Cisplatin (CIS), Etoposide (ETOP), Luteinizing Hormone Receptor Hormone (LHRH) agonist, Bicalutamide (BIC) against Advanced Solid Tumors (AST), Giant Cell Glioblastoma (GCG), Adrenocortical (ADC), Solid Tumors (ST), Small Cell lung Cancer (SCLC) and Metastatic Prostate Cancer (MPC) are highlighted for Maximum Tolerated Doses (MTD). Side effects are abbreviated as ADP (Abdominal Pain), Neut (Neutropenia), Throm (Thrombocytopenia), Gastrointestinal symptoms (GI), Fatigue (FAT), Anemia (Anem) and Nausea (Nau). Objective Response Rates (ORR), Complete Responses (CR), Partial Responses (PR), Prostate-Specific Antigen levels (PSA) and percentage patients (%) from the whole group experiencing disease stabilization effects are also highlighted (Stab.). The clinical trials reference numbers are highlighted in bold (left column), and the corresponding references highlighted in the column on the right (Ref). Unavailable data is highlighted by ‘-‘

From: BH3-mimetics: recent developments in cancer therapy

AT-101

Phase

Patients

Patients

Combined

Disease

Adverse Effects

ORR

Stab.

Ref

NCT00891072

I

24

Pre-treated

CARB/PAC

AST

ADP/Neut/Throm

4.16% CR; 16.66% PR

33%

[401]

NCT00540722

II

56

Untreated (3 wks)

-single-

GCG

GI/FAT

–

–

–

NCT00848016

II

29

–

-single-

ADC

Anem/Naus/FAT

–

–

–

NCT00544596

I

27

Untreated (4 wks)

CIS/ETOP

ST/SCLC

–

–

–

–

NCT00773955

II

14

Pre-treated

-single-

SCLC

Anem/GI

0% CR; 0% PR

–

–

NCT00666666

II

55

Untreated (4 wks)

LHRH/BIC

MPC

Anem/GI/AT

18–60% Decreased PSA

–

–